Menstrual bleeding: diagnosis and treatment
Heavy menstrual bleeding (HMB) is a common reason for women and adolescent girls to seek medical advice. This pathology increases maternal morbidity and mortality rates in pregnant women with existing anemia associated with heavy menstrual bleeding. The underestimation of the severity of this condition continues to be a pressing problem among clinicians and patients. HMB considerably worsens quality of life; therefore the purpose of therapy for this condition is to reduce menstrual blood loss, to normalize iron metabolic parameters, and to significantly improve quality of life.Andreeva E.N., Sheremetyeva E.V.
Keywords
heavy menstrual bleeding
anemia
quality of life
maternal morbidity
References
- National Collaborating Centre for Women’s and Children’s Health. Heavy menstrual bleeding clinical guideline 44. London: RCOG Press for NICE; 2007.
- Bitzer J., Serrani M., Lahav A. Women’s attitudes towards heavy menstrual bleeding, and their impact on quality of life. Open Access J. Contraception. 2013; 4: 21-8.
- Palep-Singh M., Prentice A. Epidemiology of abnormal uterine bleeding. Best Pract. Res. Clin. Obstet. Gynaecol. 2007; 21(6): 887-90.
- Narice B.F., Delaney B., Dickson J.M. Endometrial sampling in low-risk patients with abnormal uterine bleeding: a systematic review and meta-synthesis. BMC Fam. Pract. 2018; 19(1): 135.
- Sriprasert I., Pakrashi T., Kimble T., Archer D.F. Heavy menstrual bleeding diagnosis and medical management. Contracept. Reprod. Med. 2017; 2: 20.
- Чернуха Г.Е., Ильина Л.М., Иванов И.А. Аномальные маточные кровотечения: ставим диагноз и выбираем лечение. Гинекология. 2018; 20(4): 4-8. [Chernukha G.E., Ilina L.M., Ivanov I.A. Abnormal uterine bleeding: make a diagnosis and choose a treatment. Gynecology. 2018; 20 (4): 4-8. (in Russian)].
- Sasaki L.M.P., Andrade K.R.C., Figueiredo A.C.M.G., Wanderley M.D.S., Pereira M.G. Factors associated with malignancy in Hysteroscopically Resected Endometrial Polyps: A Systematic Review and meta-analysis. J. Minim. Invasive Gynecol. 2018; 25(5): 777-85.
- Munro M.G., Critchley H.O.D., Fraser I.S.; FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int. J. Gynaecol. Obstet. 2018; 143(3):393-408.
- Edelman A., Lew R., Cwiak C., Nichols M., Jensen J. Acceptability of contraceptive-induced amenorrhea in a racially diverse group of US women. Contraception. 2007; 75: 450-3.
- Андреева Е.Н. Обильные менструальные кровотечения: современный подход к проблеме и пути ее решения. Проблемы репродукции. 2015; 21(6): 39-47. [Andreeva E.N. Abundant menstrual bleeding: a modern approach to the problem and ways to solve it. Reproduction problems. 2015; 21 (6): 39-47. (in Russian)]. doi: 10.17116 / repro201521639-47
- Fraser I.S., Langham S., Uhl-Hochgraeber K. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev. Obstet. Gynecol. 2009; 4(2): 179-89.
- Lam C., Anderson B., Lopes V., Schulkin J., Matteson K. Assessing abnormal uterine bleeding: are physicians taking a meaningful clinical history? J. Womens Health (Larchmt). 2017; 26 (7): 762-7.
- Heavy menstrual bleeding Guideline Development Group membership and acknowledgements. NICE: 2018.
- American College of Obstetricians and Gynecologists. Management of acute abnormal uterine bleeding in non-pregnant women. Committee Opinion №557. Obstet. Gynecol. 2013; 121(4): 891-6.
- Чернуха Г.Е., Немова Ю.И. Диагностика и медикаментозная терапия маточных кровотечений с позиций международных рекомендаций. Акушерство и гинекология: новости, мнения, обучение. 2013; 2: 12-7. [Chernukha G.E., Nemova Yu.I. Diagnosis and drug therapy of uterine bleeding from the standpoint of international recommendations. Obstetrics and gynecology: news, opinions, training. 2013; 2: 12-7. (in Russian)].
- Shabaan M.M., Zakherah M.S., El-Nashar S.A., Sayed G.H. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: A randomized clinical trial. Contraception. 2011; 83: 48-54.
- Sayed G.H., Zakherah M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fi broid-related menorrhagia. Int. J. Gynaecol. Obstet. 2011; 112: 126-30.
- Lukes A.S., Moore K.A., Muse K.N., Gersten J.K., Hecht B.R., Edlund M.et al. Tranexamic acid treatment for heavy menstrual bleeding: A randomized controlled trial. Obstet. Gynecol. 2010; 116(4): 865-75.
- Fraser I.S., Jensen J.T. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum. Reprod. 2011; 26(10):2698-708.
- Jensen J.T., Parke S., Mellinger U. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet. Gynecol. 2011; 117 (4): 777-87.
- Актуальная инструкция по медицинскому применению препарата Клайра® № ЛП-000010 от 06.02.2019. [Actual instructions for the medical use of the drug Klayra ® № LP-000010 from 06.02.2019. (in Russian)].
- Yu Q., Zhou Y., Suturina L., Jaisamrarn U., Lu D., Parke S. Efficacy and safety of estradiol valerate/dienogest for the management of heavy menstrual bleeding: a multicenter, double-blind, randomized, placebo-controlled, phase III clinical trial. J. Womens Health (Larchmt). 2018; 27(10): 1225-32.
- Briggs P., Serrani M., Vogtländer K., Parke S. Continuation rates, bleeding profile acceptability, and satisfaction of women using an oral contraceptive pill containing estradiol valerate and dienogest versus a progestogen-only pill after switching from an ethinylestradiol-containing pill in a real-life setting: results of the CONTENT study. Int. J. Womens Health. 2016;8: 477-87.
- Всемирная Организация Здравоохранения. Медицинские критерии приемлемости использования методов контрацепции. 5-е изд. 2015. [World Health Organization. Medical eligibility criteria for contraceptive use. 5th ed. 2015. (in Russian)].
- Nelson A., Parke S., Mellinger U., Zampaglione E., Schmidt A. Efficacy and safety of a combined oral contraceptive containing estradiol valerate/dienogest: results from a clinical study conducted in North America. J. Womens Health (Larchmt). 2014; 23(3): 204-10.
- Dinger J., Do Minh T., Heinemann K. Impact of estrogen type on cardiovascular safety of combined oral contraceptives. Contraception. 2016; 94(4):328-39.
Received 12.04.2019
Accepted 19.04.2019
About the Authors
Andreeva, Elena N., MD, professor, deputy director of the center - director of the Institute of Reproductive Medicine of the National Medical Research Centerfor Endocrinology of the Ministry of Health of Russia. 117036, Russia, Moscow, Dmitry Ulianov str. 11. Tel.: +79161270268. Email: endogin@mail.ru; professor,
Department of Reproductive Medicine and Surgery, Moscow State Medical and Dental University A.I. Evdokimova Ministry of Health of Russia.
127473, Russia, Moscow, Delegatskaya str. 20, bldg. 1. https://orcid.org/0000-0001-8425-0020 , eLibrary SPIN: 1239-2937
Sheremetyeva, Ekaterina V., MD, endocrinologist, obstetrician-gynecologist at the Department of the Consultative and Diagnostic Center of the National Medical Research Center of Endocrinology of the Ministry of Health of Russia. 117036, Russia, Moscow, Dmitry Ulyanov str. 11. Tel.: +79639984022. Email: s1981k@yandex.ru
https://orcid.org/0000-0001-7177-0254, eLibrary SPIN: 9413-5136
For citations: Andreeva E.N., Sheremetyeva E.V. Menstrual bleeding: diagnosis and treatment. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2019; (5): 186-92. (in Russian)
http://dx.doi.org/10.18565/aig.2019.5.186-192
Similar Articles
